Orexo ABORXOF 34 Days Payable is 17,165.61 as of Mar. 2026, which is 7298% above its 10-year median of 232.04. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Orexo AB ranks better than 97.07% on this metric.
Orexo AB's average Accounts Payable for the
three
months ended in Mar. 2026 was $8.09 Mil. Orexo AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.04 Mil.
Hence, Orexo AB's Days Payable for the
three
months ended in Mar. 2026 was 17,165.61.
The historical rank and industry rank for Orexo AB's Days Payable or its related term are showing as below:
ORXOF'
s Days Payable Range Over the Past 10 Years
Min: 86.55 Med: 232.04 Max: 1687.81
Current: 1293.48
During the past 13 years, Orexo AB's highest Days Payable was 1687.81. The lowest was 86.55. And the median was 232.04.
ORXOF's Days Payable is ranked better than 97.07% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs ORXOF: 1293.48
Orexo AB's Days Payable
increased
from Mar. 2025 (758.71) to Mar. 2026 (17,165.61).
It may suggest that Orexo ABdelayed paying its suppliers.
Orexo AB Days Payable Related Terms
Orexo AB Days Payable Historical Data
* Premium members only.
The historical data trend for Orexo AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Orexo AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Orexo AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOF) has a Days Payable of 17,165.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orexo AB and its competitors. This is 7298% above median its historical median of 232.04. Over the past decade, Orexo AB's Days Payable has ranged from 86.55 to 1,687.81. According to the industry distribution chart, Orexo AB ranks #27 out of 923 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Orexo AB's Days Payable too high?
Orexo AB's current Days Payable of 17,165.61 is 7298% above median its 10-year median of 232.04. Over the past 10 years, this metric has ranged from a low of 86.55 to a high of 1,687.81. The Drug Manufacturers industry median Days Payable is 90.98. Orexo AB's value of 17,165.61 is 18767.5% above this industry median. Based on the distribution chart, Orexo AB ranks #27 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #27 out of 923 companies for Days Payable. This places Orexo AB in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Orexo AB's value of 17,165.61 is 18767.5% above this benchmark. Historically, Orexo AB's own Days Payable has ranged from 86.55 to 1,687.81 over the past decade. While the company's 10-year median is 232.04 vs. the industry median of 90.98, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Days Payable of 17,165.61 is 18767.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Days Payable is 17,165.61, which is 7298% above median its own 10-year median of 232.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Days Payable is 17,165.61, which is 7298% above median its 10-year median of 232.04 and 18767.5% above the Drug Manufacturers industry median of 90.98. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Days Payable is 17,165.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Days Payable: 17,165.61 (7298% above median its 10-year median of 232.04)
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 18767.5% above the Drug Manufacturers median (#27 of 923)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
